Products
Online Inquiry
Repotrectinib
Cat. No.:
0225LY-0783
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Repotrectinib is a powerful inhibitor of ALK, ROS1, and TRK, with IC50 values of 1.01 nM for wild-type ALK and 5.3 nM for SRC.
Synonym:
1802220-02-5; Augtyro; Ropotrectinib; (3R,11S)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaen-14-one; 1,15-Etheno-1H-pyrazolo(4,3-F)(1,4,8,10)benzoxatriazacyclotridecin-4(5H)-one, 11-fluoro-6,7,13,14-tetrahydro-7,13-dimethyl-, (7S,13R)-; (13E,14E,3R,6S)-45-fluoro-3,6-dimethyl-5-oxa-2,8-diaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-4(1,2)-benzenacyclononaphan-9-one; (1Z)-6-Fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentaazatetracyclo(13.5.2.04,9.018,22)docosa-1,4,6,8,15,19,21-heptaen-14-one
CAS No.:
1802220-02-5
Compound CID:
135565923
Formula:
C18H18FN5O2
Formula Weight:
355.37
Specification
Targets&IC50:
Src: 5.3 nM; ALK (L1196M): 1.08 nM; ALK (G1202R): 1.26 nM; ALK (WT): 1.01 nM
Relative Density:
1.46 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Repotrectinib can be used in precision medicine research to study the inhibition of ROS1 and TRK fusions, especially in resistant tumor models.
Library Information
Target:
Src; ALK; Trk receptor
Receptor:
Src; ALK; Trk receptor
Pathways:
Angiogenesis; Tyrosine kinase/adaptors; Immunology/Inflammation
Plate Number:
AOCL-11
Plate Location:
b2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
60 mg/mL; 168.84 mM
